NASDAQ : ZURA

Zura Bio Limited — Company profile

Healthcare · Biotechnology · United States

Last price 4.04 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 389.15M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.

Details

NameZura Bio Limited
SectorHealthcare
IndustryBiotechnology
Employees40
Founded2022
CeoSandeep Kulkarni
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IsinKYG9TY5A1016
CusipG9TY5A101
Cik1855644
Sic2836
Share ClassClass A Shares

Key executives

NameTitle
Dr. Sandeep Chidambar Kulkarni M.D.Co-Founder, Chief Executive Officer and Director
Kimberly Ann Davis J.D.Chief Operating Officer, Chief Legal Officer and Corporate Secretary
Dr. Kiran Nistala MBBS, Ph.D.Chief Medical Officer and Head of Development
Marlyn MathewVice President of Finance and Accounting and Principal Financial & Accounting Officer
Dr. Gary Whale Ph.D.Chief Technology Officer
Theresa LowryChief Human Resources Officer
Muzammil MustufaChief Business Officer

Contact

Address1489 W. Warm Springs Road, Suite 110, Henderson, Nevada 89014, United States
Phone702 825 9872
Websitehttps://zurabio.com